Company intelligence / Profile preview

Pluritrade

Ownership: Private
Employees: ~180
Development stage: Other

Overview

Pluri Inc. (formerly Pluristem Therapeutics) is a biotechnology company focused on cell therapy and regenerative medicine, utilizing its proprietary 3D cell expansion technology. The company has programs in clinical development up to Phase 3 for indications like muscle injury and acute radiation syndrome, and is also expanding into cellular agriculture (foodtech/agtech) through its platform.

Therapeutic areas: OtherOncologyHematology
Modalities: Cell therapyMesenchymal stem cell therapyStem cell therapy
Industry: Biotech

Partnerships

U.S. Department of Defense’s Armed Forces Radiobiology Research InstituteNIH/NIAIDmultiple undisclosed partners for CDMO services

Beyond the preview

Go deeper on Pluritrade.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluritrade.

Explore the full profile